SNY News and Press, Sanofi From 05/13/24

2024-05-13 13:53:13 ET More on AstraZeneca, Pfizer Pfizer's Bottom May Be Here - Its Rich Yield Is Tempting Pfizer: A 6% Yield And At 10-Year Lows Pfizer Stock: Not A Value Trap, Here's Why Pfizer to settle over 10,000 Zantac-related cancer claims: report ...

2024-05-13 10:09:30 ET More on Sanofi, Fulcrum Sanofi Q1: Wait And See For Now (Downgrade) Sanofi: Q1 Earnings Reflect Growth And Strategic Acquisitions (Rating Upgrade) Sanofi 2024 Q1 - Results - Earnings Call Presentation Biggest stock movers today: ARM, ZK...

― Entered into a collaboration and ex-U.S. license agreement with Sanofi for the development and commercialization of losmapimod ― ― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in the fourt...

― Sanofi receives exclusive rights to commercialize losmapimod in all territories outside the U.S.; Fulcrum retains full U.S. commercialization rights ― ― Fulcrum will receive an upfront payment of $80.0 million, and is eligible to receive $975.0 million in potentia...

2024-05-13 05:49:56 ET More on related stocks: Novavax: Sanofi Partnership Revitalizes My Magnum Opus Novavax, Inc. (NVAX) Q1 2024 Earnings Call Transcript Spotlight On The CPI Print, Walmart Earnings, Google Event And Zeekr Buzz Sanofi to invest over €...

2024-05-13 03:29:35 ET More on Sanofi Sanofi Q1: Wait And See For Now (Downgrade) Sanofi: Q1 Earnings Reflect Growth And Strategic Acquisitions (Rating Upgrade) Sanofi 2024 Q1 - Results - Earnings Call Presentation Novavax surges as Sanofi COVID vaccine deal ...

If approved, Dupixent would be the first treatment in the U.S. indicated for adolescents aged 12-17 years with inadequately controlled CRSwNP, a condition driven in part by underlying type 2 inflammation that obstructs the sinuses and nasal passages and can lead to a loss of sense of smell ...

2024-05-12 13:07:18 ET Summary Novavax announced Q1 2024 results with a beat on EPS and a miss on revenue, causing a surge in premarket trading. Novavax finalized a licensing agreement with Sanofi worth up to $1.2B, boosting its COVID-19 vaccine commercial performance. The San...

2024-05-11 23:18:05 ET Summary IGM Biosciences is developing a different class of antibodies to improve on the classic IgG antibodies. Their most advanced project, aplitabart, is being tested in a clinical trial for metastatic colorectal cancer. The company has a decent cash p...

2024-05-11 07:59:50 ET More on Novavax Novavax Ditches 'Going Concern,' Embraces Sanofi Safety Net (Rating Upgrade) Novavax Q1 2024 Earnings Preview: Success In New Commercial COVID Markets Unlikely Novavax, Inc. (NVAX) TD Cowen's 44th Annual Health Care Conference -...